Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 12:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 3,875 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Healthy Volunteer
Interventions: BIIB122, Rabeprazole; Drug
Lead sponsor: Biogen; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Volunteers
Interventions: Abrocitinib tablet, Abrocitinib Suspension F1, Abrocitinib Suspension F2, Abrocitinib Suspension F3, Abrocitinib Suspension F4, Abrocitinib Suspension F5, Abrocitinib Suspension F6, Famotidine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Severe Mental Disorder
Interventions: Individual placement support (IPS); Other
Lead sponsor: Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente; Other
Eligibility: 18 Years to 60 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: New York, New York

Conditions: Depression
Interventions: Ketamine, Diphenhydramine; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: New York, New York

Conditions: Respiratory Pathogens, Upper Respiratory Tract Illness, Lower Respiratory Tract Illness, Acute Respiratory Infection
Interventions: Results available to provider; Diagnostic Test
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 1 Month to 18 Years
Enrollment: 913 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Stroke
Interventions: Neurostimulation Exosuit; Device
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 18 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Immune Surveillance
Interventions: Placebo, Nutraceutical blend; Dietary Supplement
Lead sponsor: Natural Immune Systems Inc; Other
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Klamath Falls, Oregon

Conditions: Wave Form Signals Coming From the Eye in a Healthy Cohort
Interventions: HITT device; Device
Lead sponsor: Rebiscan, Inc.; Industry
Eligibility: 11 Years to 21 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Vitamin B6 Deficiency
Interventions: Arm 1 glycine and leucine, Arm 2 Intervention of Serine and methionine infusion; Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 20 Years to 40 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Congenital Heart Diseases, Cardiac Diseases
Interventions: Not listed
Lead sponsor: Matthias Stuber; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 9
States / cities: Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 6 more

Conditions: SARS-CoV 2
Interventions: Clungene rapid test cassette; Diagnostic Test
Lead sponsor: Fadi Haddad, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 3
States / cities: La Mesa, California • San Diego, California

Conditions: Physical Disability
Interventions: Life Space Assessment Scale, 6-Minute Push Test, Forward Push Test, Wheelchair Slalom Test, Craig Handicap Assessment and Reporting Technique, PART-O, GPS Tracking; Other
Lead sponsor: Allina Health System; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Golden Valley, Minnesota

Conditions: Diabetes Mellitus
Interventions: saxagliptin, metformin XR, saxagliptin + metformin XR (FDC tablet); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: tofacitinib modified release (MR); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hepatitis C, Chronic
Interventions: Telaprevir, Pegylated Interferon Alfa-2a, Ribavirin; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 55
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 42 more

Conditions: Solid Tumors
Interventions: Tesetaxel 10 mg with and then without food, Tesetaxel 10 mg without and then with food; Drug
Lead sponsor: Genta Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Edema
Interventions: Torsemide; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Time Restricted Eating, Obesity
Interventions: Time Restricted Eating; Behavioral
Lead sponsor: University of Mississippi, Oxford; Other
Eligibility: 19 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Oxford, Mississippi

Conditions: Shock, Septic
Interventions: Lactated Ringer, Normal saline; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 6 Months to 17 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: 330 mg pregabalin controlled release, 300 mg pregabalin immediate release; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: AIDS/HIV PROBLEM
Interventions: Not listed
Lead sponsor: Gaia Medical Institute; Industry
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Underlying Liver Disease, Hepatitis, Fibrosis of Liver, Cirrhosis With Suspicion of Liver Cancer, Lesion on a Prior Ultrasound, CT or Outside MRI
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: HIV/AIDS
Interventions: bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF), Standard initiation of antiretroviral therapy (ART); Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 15 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Aurora, Colorado • Omaha, Nebraska

Conditions: Hypertension
Interventions: Improve clinic based measurement of blood pressure, Provider education system to promote patient-centered care, Introduce care management system in clinics; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 66,570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants

A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.

Individual Placement and Support Mexico

Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients

The RAPID Trial: Assessing Point-of-care Influenza and Other Respiratory Virus Diagnostics

Neurostimulation Exosuit Augmented Training (NEAT) in the Clinic

Clinical Trial on Rapid Immune Modulating Effects

Neuro-ocular Baselines in a Sports Setting

Vitamin B6 Dependence of One-Carbon Metabolism

An International Multicenter, Multivendor Evaluation of the Free-Running Framework for Cardiac Function

IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With the Standard Method of COVID19 Testing.

Manual Wheelchair Speed, Maneuverability, and Endurance and Community Access

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)

A Study In Adult Healthy Volunteers To Asses Once Daily (QD) Dosing With The Selected Age-Appropriate Modified Release (MR) Formulations

Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype

Effects of Food on the Pharmacokinetics of Tesetaxel 10 mg Capsules

Bioequivalency Study of Torsemide Tablets Under Fasting Conditions

Time-restricted Eating Acceptability, Efficacy and Safety in Obesity

Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis: A Pilot Feasibility Study

A Study To Assess The Pharmacokinetics, Safety, And Tolerability Of A Pregabalin Controlled Release Formulation Administered Following Various Sized Caloric Meals As Compared To The Pregabalin Immediate Release Formulation

Rapid Oral Test for Therapeutic Response in HIV/AIDS Patients

Rapid 10-Minute Liver MRI Protocol in Patients With Suspected Hepatocellular Carcinoma

Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIV

Multi-Method Health System Quality Improvement Intervention to Reduce Hypertension Disparities